Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
Limit direct sun exposure for at least 24-48 hours
Each vial is carefully manufactured and sealed to ensure product stability and sterility during storage and laboratory handling
Moreover, data from a meta-analysis have illustrated the neuroprotective effects of UA in reducing infarction, BBB damage, edema, and neurological deficits [149]
K.BeatriceG.et al (2018)
US$ 27.80
US$ 23.52
US$ 25.56
